Jaguar Health completes enrollment in pivotal Phase 3 OnTarget trial; raises $1.86M in PIPE financing

Jaguar Health, Inc.

Enrolled target 256 patients in Phase 3 OnTarget trial for crofelemer to prevent cancer therapy-related diarrhea; top-line results expected early Q4 2023.
Private placement raises ~$1.86M via 137 Series G convertible preferred shares (convertible at $0.5423) and 6,850,000 warrants at $0.48 exercise price.
Warrants exercisable from later of Jan 1, 2024 or stockholder approval, for 5 years; no anti-dilution or variable pricing.
Standstill agreement with Iliad, Uptown, Streeterville suspends royalty payments for up to 6 months; they receive warrants for ~3.82M shares.
Company agrees not to issue additional equity securities before Oct 22, 2023, except with PIPE investor consent.

item 1.01 item 5.03 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jaguar Health, Inc.: Created Series G Preferred Stock via Certificate of Designation, establishing its preferences, rights, and limitations.

Change: charter amendment

Exact text from the filing

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series G Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue the Series G Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series G Preferred Stock are set forth in the Certificate of Designation.

View on SEC.gov

18 governance changes filed in the last 30 days. Browse all governance changes →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.